36.6 F
New York
Wednesday, January 27, 2021

Fulgent Genetics [NASDAQ: FLGT] Announces COVID-19 Testing Deal In Ohio

Must read

JPMorgan [NYSE: JPM] Announced To Initiate A Digital Retail Bank In The United Kingdom

JPMorgan Chase revealed that the company will launch a new digital retail bank in the United Kingdom offering the customer of the region...

Humanigen [NASDAQ: HGEN] Announces Expansion Of Manufacturing Agreement With Ajinomoto Bio-Pharma

Humanigen Inc revealed that the company has extended the manufacturing agreement with  Ajinomoto BioPharma to support the fill-finish of Lenzilumab. The Lenzilumab is...

Synchrony [NYSE: SYF] Announced To Purchase Allegro Credit

Synchrony Financials revealed that the company entered into a definitive contract to Purchase Allegro Credit. Allegro Credit's customer base and merchant network will...

Vericel Corp [NASDAQ: VCEL] Names Joe Mara As The New CFO

Vericel Corporation revealed that the company has named Joe Mara as the CFO of the company. He has over more than 20 years...

Fulgent Genetics, Inc. [NASDAQ: FLGT] has announced Wednesday that it has been chosen by the Ohio Department of Rehabilitation and Correction (ODRC) to fulfill the COVID-19 testing needs.

The Ohio Department of Rehabilitation and Correction will get benefit from Fulgent’s RT-PCR testing capabilities and Enterprise Platform. The Ohio department will test its approximately 14,000 employees on a routine basis.

The partnership between the Ohio department and Fulgent includes on-site testing at locations across the state. It will leverage Fulgent’s Enterprise Platform. 

Fulgent Genetics, Inc. shares were trading up 7.37% at $41.81 at the time of writing on Tuesday. FLGT share price went from a low point around $6.70 to briefly over $52.47 in the past 52 weeks, though shares have since pulled back to $41.81.

Fulgent Genetics market capitalization has remained high, hitting $927.76 million at the time of writing. This company had a trading volume of 1.02 million as compared to the average volume of 932.33K.

If we look at its profitability, its return on assets, equity, and investment is 3.00%, 3.30%, and -0.60%. If we look at its liquidity, it has a current ratio of 6.30.

The platform of Fulgent will help the ODRC to provide the on-site testing process. It will give each employee a QR code or using their employer ID which is linked to their sample via a barcode scan.

The sample then returned to Fulgent for processing and supervision. The employees will get their test results within 24 hours of sample receipt.

More articles

Latest article

A Paychex [NASDAQ: PAYX] Subsidiary Announces Strategic Collaboration With Zoho Books

SurePayroll, a subsidiary of Paychex company revealed that the company has formed a collaboration with Zoho books. SurePAyroll is a provider of small...

MGP Ingredients [NASDAQ: MGPI] Announced To Acquire Luxco and Its Affiliate Companies

MGP Ingredients  revealed a definitive contract to purchase Luxco, Inc and its affiliated companies. Luxco is an alcohol beverage company with more than 60...

Conformis [NASDAQ: CFMS] Entered A Non-Exclusive agreement with SITES Medical

Conformis Inc revealed that the company inked a development and supply contract with sites medical. Both of the companies will work together to...

Colliers International [NASDAQ: CIGI] Announces Executive Leadership Changes For Australian Business

Colliers International  reported that the company has named Malcom Tyson as the new Chief Executive Officer. He is appointed as the CEO so...

Korn Ferry [NYSE: KFY] Announces Expansion Of Its Footprint In Russian Market

Korn Fery revealed that the company is expanding its footprint in Russia. Moreover, it is adding a high expertise team of executive search...

Haemonetics [NYSE: HAE] To Purchase Cardiva For An Upfront Payment Of $475M

Haemonetics Corporation revealed that the company has inked a definitive contract to purchase Cardiva Medical Inc. Under the contract, Haemontics will pay an...

Philips [NYSE: PHG] To Purchase Capsule Technologies For Cash Consideration Of USD 635M

Koninklijke Philip revealed that the company has inked a contract to purchase Capsule technologies. The company will pay a cash price of $636...

Thermo Fisher Scientific [NYSE: TMO] To Purchase Mesa Biotech For Approx. $450M In Cash

Thermo fisher scientific inc revealed that the company has signed a definitive contract to purchase Mesa Biotech. Thermo will pay a value price...